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High-quality research is essential for identifying the 
health needs and improving the health outcomes of a 
population.[1] Health research drives development, as 
it generates the knowledge needed to improve health 
systems performance and, ultimately, health and 
health equity.[2] Remarkable medical advances have taken place in 
South Africa (SA), such as the invention of computed tomography[3] 
and the first human heart transplant,[4] through investment in 
health research by government and industry. There has, however, 
been a perceived reduction in state expenditure on health research 
in real terms from the beginning of the 1980s,[5] characterised by a 
redistribution of state expenditure in the healthcare system towards 
primary healthcare and an apparent stagnation in real terms in the 
level of government-funded health research expenditure between 
1996 and 2006.[6]
The Consensus Report on Revitalising Clinical Research in South 
Africa of the Academy of Science of South Africa (ASSAf)[5] has 
identified the low level of investment in clinical research as a major 
factor in SA’s declining clinical research performance. This report 
recommended inter alia that developing countries should invest 
at least 2% of their gross domestic product (GDP) in research 
and development (R&D), and that 20% of gross expenditure on 
R&D (GERD) (i.e. 0.4% of the GDP) should be allocated to health 
research.[5] Against this background, the SA Ministry of Health, the 
Department of Health (DoH) and the National Health Research 
Committee (NHRC) have made a series of commitments to increase 
investment in health research through the country budget and the 
national health budget. For example, the National Health Research 
Policy of 2001[7] proposed that the country budget for health 
research should be raised to at least 2% of total public sector health 
expenditure. Subsequently, the Ministry of Health committed itself 
through the Mexico, Bamako and Algiers declarations to allocate at 
least 2% of the national health budget to research.[8-10] In addition, the 
2011 National Health Research Summit report[11] recommended that 
the national DoH increase its funding for health research to achieve 
the 2% target of the national health budget.
This multiplicity of commitments, compounded by the lack 
of a detailed information system, renders interpretation of these 
commitments a complex process. The NHRC, which is a statutory 
body tasked with setting priorities for health research in SA, has 
therefore conducted an audit to determine the proportion of gross 
expenditure on R&D that has been spent on health research (as a 
proxy for the proportion of country budget spent on health research) 
in the past decade, as well as the proportion of the budget of the DoH 
that was spent on research in the period 2009/10 - 2012/13. We have 
compared these data with internationally accepted benchmarks as a 
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The Mexico (2004), Bamako (2008) and Algiers (2008) declarations committed the South African (SA) Ministry of Health to allocate 2% 
of the national health budget to research, while the National Health Research Policy (2001) proposed that the country budget for health 
research should be 2% of total public sector health expenditure. The National Health Research Committee has performed an audit to 
determine whether these goals have been met, judged by: (i) health research expenditure as proportions of gross expenditure on research 
and development (GERD) and the gross domestic product (GDP); and (ii) the proportion of the national health and Department of Health 
budgets apportioned to research. We found that total expenditure on health research in SA, aggregated across the public and private sectors, 
was R3.5 billion in 2009/10, equating to 16.7% of GERD. However, the total government plus science council spend on health research 
that year was only R729 million, equating to 3.5% of GERD (0.03% of the GDP) or 0.80% of the R91.4 billion consolidated government 
expenditure on health. We further found that R418 million was spent through the 2009/2010 Health Vote on health research, equating to 
0.46% of the consolidated government expenditure on health or 0.9% of the R45.2 billion Health Vote. Data from other recent years were 
similar. Current SA public sector health research allocations therefore remain well below the aspirational goal of 2% of the national health 
budget. We recommend that new, realistic, clearly defined targets be adopted and an efficient monitoring mechanism be developed to track 
future health research expenditure.
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way to judge historical trends and to provide 
a benchmark for future aspirations.
Sources of information
We used several sources of information on 
public and private expenditure on health 
research in SA, including the national surveys 
of research and experimental development of 
the Department of Science and Technology 
(1991/2 and 2009/10);[12-14] the Global 
Forum for Health Research (GFHR) reports 
Financing Research and Development for 
Health[15] and Monitoring Financial Flows for 
Health Research;[16] the National Treasury’s 
2013 Estimates of National Expenditure;[17] 
the ASSAf report Revitalising Clinical Research 
in South Africa;[5] the National Treasury’s 
medium-term budget policy statements (2010 
and 2012);[18,19] the 2001 Health Research 
Policy in South Africa document;[7] and the 
2011 National Health Research Summit report 
Strengthening Research for Health, Innovation 
and Development in South Africa.[11]
Findings
Various recommendations for the mini-
mum level of investment in health research, 
based on different metrics, are outlined in 
Table 1.[5,7,9,20] The 2001 Health Research Policy 
in SA was developed through consultation of 
relevant stakeholders by the Essential National 
Health Research Committee, the forerunner 
of the NHRC. This policy was adopted by 
the national DoH, but it was not presented to 
Cabinet or gazetted by Parliament.
In SA, health research is funded from 
multiple sources including local (public 
and private sectors) and foreign agencies. 
Moreover, in the public sector, health research 
funding is not exclusively provided by the 
DoH but also by the departments of Science 
and Technology and of Higher Education 
and Training. In view of the complexities of 
the SA health research funding model, we 
have used GERD – both as a proportion of 
the GDP and in absolute terms – together 
with the proportion of GERD (both in 
absolute and percentage terms) allocated to 
health research as surrogate indicators of 
total health expenditure on research in this 
country. Furthermore, we have established 
the total government sector expenditure 
on health research, as well as the specific 
DoH expenditure on health research, as 
proportions of the consolidated government 
expenditure on health. In the absence of 
accurate definitions of the ‘health research 
budget’ and ‘total public health expenditure’ 
in the National Health Research Policy of 
2001, we used the consolidated government 
expenditure outcome on health as a proxy 
for the national health budget and the Health 
Vote as a proxy for the DoH’s budget.
In this audit, we assessed performance 
against two metrics: (i) health research 
expenditure (government sector and total) 
as proportions of the GDP and GERD; and 
(ii) the proportion of national health budget 
and DoH budget apportioned to research.
Gross expenditure on R&D
Fig. 1 illustrates GERD for a basket of high- 
and low-middle-income countries (HICs 
and LMICs, respectively) for the year 2006, 
as well as for India (2004), New Zealand 
and Mexico (2005) and China (2007).[15,16] 
The SA data relate to aggregated public and 
Table 1. Recommendations for the minimum level of investment in health research using different measures
Organisation Metric
DoH, SA: 2001 Health Research Policy in South 
Africa[7]
The health research budget be raised to at least 2% of total public health expenditure. In 
this analysis, we have used GERD as a proxy for estimating the proportion of national 
expenditure that is spent on health research
WHO: Ministerial Summit on Health Research and 
Development: The Bamako Call to Action[9]
At least 2% of national health budgets be apportioned to research. In this analysis, we have 
used the consolidated government expenditure on health as the national health budget
ASSAf: Consensus Report on Revitalising Clinical 
Research in South Africa[5]
2% of the GDP be invested in indigenous science and technology development, with 
health research receiving at least 20% of this amount
COHRED[20] 2% of a developing nation’s GDP be allocated to R&D
Third World of Academy of Sciences[20] 2% of the GNP of developing countries be a minimum investment in indigenous science 
and technology development, with health research receiving 10% of this amount
DoH = Department of Health; SA = South Africa; GERD = gross expenditure on research and development; WHO = World Health Organization; ASSAf = Academy of Science of South Africa; 
GDP = gross domestic product; COHRED = Council on Health Research and Development; R&D = research and development; GNP = gross national product.
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Fig. 1. Gross expenditure on research and development as a percentage of the gross domestic product. 
Data are for 2006 in general, except for India (2004), New Zealand and Mexico (2005), and China 
(2007). (GERD = gross expenditure on research and development; GDP = gross domestic product.)
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private sector funding sources and reveal 
that ~0.9% of the GDP was spent on R&D 
in 2006, which was well below the ASSAf 
target of 2% for a middle-income country. 
Countries that invested less than 0.9% of 
their GDP on R&D include India, Mexico 
and Greece, while China spent 1.49% of 
its GDP on R&D and established market 
economies spent 1.8 - 4.3%.
Analysis of GERD in SA for the period 
1991 - 2009 reveals that it declined between 
1991 and 1994 (Fig. 2). Since 1994 there 
has been a steady increase in the nominal 
value of GERD from under R4 billion to 
R20.9 billion in 2009/10, equating to an 
average increase of 11.7% per year during 
this period, which is well above the average 
inflation rate of ~6.5% for the same period 
(based on consumer price index (CPI) data 
from Statistics South Africa[21]). GERD in 
SA therefore increased ~2-fold in real terms 
over the period 1994 - 2009. Interestingly, 
although there was a R1.1 billion increase 
in public research expenditure in 2009/10 
aggregated across government departments, 
science councils and higher education, the 
9.7% reduction in research expenditure in 
the private sector in that year resulted in 
an overall decline in GERD from R21.04 
billion in 2008/9 to R20.9 billion in 2009/10, 
probably reflecting the 2008/2009 global 
financial crisis. Notably, the percentage of 
the GDP spent on R&D has never exceeded 
1% (Fig. 3), despite the annual growth in the 
economy exceeding 5% between 2006 and 
2008. It declined from 0.92% in 2008/9 to 
0.87% in 2009/10, and remains persistently 
below the ASSAf target of 2%.[5]
GERD spent on health research
Fig. 4 illustrates the investment in health 
research as a proportion of GERD for various 
HICs and LMICs made in 2005,[15,16] and 
reveals that for SA this figure was 14.8%. 
Furthermore, Fig. 5 shows that over the period 
2001 - 2009, the percentage of GERD spent on 
health research has never exceeded 17%.
The total R&D spend on health research 
in SA in 2009/10 has been reported at R3.5 
billion, equating to 16.7% of GERD, which is 
close to the ASSAf recommendation of 20% 
of GERD to be spent on health research.[5] 
However, the aggregated SA government plus 
science council spend on health research in 
2009/10 was only R729 million out of the total 
R&D spend on health research of R3.5 billion. 
According to the Department of Science and 
Technology’s National Survey of Research 
and Experimental Development (2009/10),[14] 
the government sector expen diture on health 
research in that year was made up of ~R288 
million government spend and ~R441 
million science council spend; this represents 
an approximately 4-fold rise in government 
sector health research expenditure in real 
terms since 1991/2 from a nominal base of 
~R54 million (equivalent to R187 million 
in 2009, adjusted by the CPI). Government 
sector spend on health research has therefore 
risen from ~1.9% of GERD in 1991/2 to 3.5% 
in 2009/10.
Proportion of national health 
budget spent on health research
The absence of adequate information 
systems makes it difficult to track trends 
of the DoH’s investment in health R&D 
activities accurately. Blecher and McIntyre[22] 
reported that 1.1% of the total expenditure 
on health in SA in 1991/92 was spent on 
research. Fig. 6 illustrates the proportion 
of the national health budget of HICs and 
LMICs that was spent on health R&D for the 
year 2005. According to the GFHR, SA spent 
1.6% of the national health budget on R&D 
in that year.[15,16]
The National Treasury medium-term bud -
get policy statements (2010 and 2012)[18,19] 
record the consolidated government expend-
iture outcome on health as R91.4 billion in 
2009/10 and R114.1 billion in 2011/12, while 
the 2013 National Treasury Estimates of 
National Expenditure[17] records the audited 
Health Vote at R45.2 billion in 2009/10 
and R55.3 billion in 2011/12. According to 
the audited figures contained in the 2013 
Estimates of National Expenditure and the 
2013 Health Vote documents, the major 
recipients of national DoH research funding 
in SA in 2011/12 were: (i) the Health Systems 
Trust to support health systems research 
activities, including the annual South African 
Health Review and the District Health 
Barometer; (ii) the Health Information 
Management, Monitoring and Evaluation 
Unit in the DoH, to develop and maintain 
a national health information system, and 
commission and co-ordinate research; (iii) 
the Human Resources Policy Research and 
Planning Unit, which is responsible for 
medium- to long-range human resources 
planning in the national health system and 
public entities; and other agencies such as 
(iv) the National Health Laboratory Service 
and (v) the South African Medical Research 
Council (MRC). The figures for 2009/10 
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Fig. 2. Gross expenditure on research and development for South Africa from 1991 to 2009.
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through to 2012/13 are shown in Table 2, 
although it should be emphasised that the 
cumulative figures in this table are estimates, 
since not all allocations may be accounted 
for precisely in the 2013 Budget and Health 
Vote documents.
Collectively, the five major recipients of 
DoH funding for research constitute 0.46% 
(R417.9 million) and 0.35% (R403 million) of 
the consolidated government expenditure on 
health in 2009/10 and 2011/12, respectively 
(Table 2); these figures suggest that the 
DoH’s expenditure on health research has 
fallen well below the 1.6% cited by the GFHR 
for 2005.[13,14]
These estimates for 2009/10 and 2011/12 
are limited by the fact that they are derived 
from the Health Vote documents, which 
only identify five recipients of national DoH 
funding; we are aware that the DoH may 
fund other research-related activities, but 
these funding streams are not tracked and are 
therefore not reflected in the above calculation. 
The lack of complete health research funding 
records clearly highlights the need for adequate 
information systems to track financial flows 
and thereby accurately gauge health research 
financing streams in SA.
Despite the caveats set out above, these 
various figures imply that in recent years an 
inadequate proportion of the national DoH 
budget has been spent on health research, 
perhaps reflecting in part the consequences 
of the Mbeki-Dlamini-Msimang denialism 
and its impact on government funding for 
medical research. This inadequate expen-
diture by the national DoH on health 
research is in sharp contrast to the fact 
that total health research expenditure in SA 
has increased from R384 million in 1991/2 
to R3.5 billion in 2009/10;[12-14] taking into 
account the CPI, this means that there 
has been a 2.6-fold increase in total health 
research expenditure in real terms over the 
past 19 years, reflecting the new role of 
business and foreign governments as major 
funders of health R&D in SA.
The MRC is the DoH’s primary research 
funding instrument; it is therefore of 
particular note that the MRC’s audited 
baseline funding from the DoH increased 
from R221 million in 2007/8 to only 
R238 million in 2011/12,[23] equating to 
an average increase of ~1.9% per annum 
over this period. However, during the 
same period the CPI increased by 6.8% 
per annum,[21] meaning that the MRC’s 
baseline funding declined by 17.4% (~R50 
million) in real terms between 2007 and 
2011. The SA National Treasury’s medium-
term expenditure forecast (2013)[17] then 
estimates an increase in the MRC’s baseline 
funding from R297 million in 2012/13 to 
R616 million in 2015/16, equating to an 
annual increase of 26.8% in nominal terms 
over the period 2011/12 - 2015/16.
We note that at present there is no direct 
public health sector research funding stream 
that flows to universities or provincial DoHs. 
For example, the conditional grant for health 
R&D of the mid-1990s has been replaced 
by the health professions training and 
development grant, which may not be used 
for research purposes. The policy framework 
of the professional education- and training-
funding  streams provided to the provincial 
health departments should therefore be 
clarified to enhance their contribution to 
health research.
Non-governmental funding for 
health research
Major contributors to health research 
funding in SA include pharmaceutical 
organisations and foreign not-for-profit 
entities such as the US National Institutes 
of Health (NIH) (which invests over $80 
million per year in SA in the form of more 
than 400 research and research training 
awards; source NIH), the Bill and Melinda 
Gates Foundation and the Wellcome Trust. 
Precise details pertaining to funding from 
some of these sources are not readily 
available, but it is estimated, for example, 
that pharmaceutical companies spent R822 
million on R&D (primarily including clinical 
trials) in SA in 2005/6.[24]
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Discussion
The origin of the various commitments 
and recommendations made by the SA 
Ministry of Health, the DoH and the 
NHRC to allocate at least 2% of the national 
health budget to research can seemingly be 
traced back to the Commission on Health 
Research for Development (COHRED) 
report of 1990, entitled Health Research: 
Essential Link to Equity in Development,[20] 
which recommended: ‘All countries should 
vigorously undertake essential national 
health research (ENHR) to accelerate health 
action in diverse national and community 
settings ... Countries should invest at least 2% 
of national health expenditures to support 
ENHR studies …’; this recommendation 
was further clarified in the report as ‘We 
recommend that all governments commit 
2% of their health budgets for ENHR.’ As 
such, it seems clear that the COHRED report 
referred to government sector expenditure 
on health research, not total expenditure, 
and we therefore suggest that the various SA 
government commitments should hence-
forth be interpreted in that light.
Against this background, the analysis 
presented here shows that the expenditure 
on health research by the DoH of R403 
million in 20011/12 equated to only 0.35% of 
the consolidated government expenditure on 
health (i.e. the national health budget) and 
only 0.73% of the Health Vote (i.e. the DoH’s 
budget). If we relax the criteria to include 
total government sector spend on health 
research, the R729 million expenditure 
recorded for 2009/10 (the latest year for 
which data are available) equated to only 
0.80% of the national health budget for 
that year. Therefore, by any logical metric – 
for example ‘DoH research expenditure 
as a proportion of its own budget’ or 
‘total government sector health research 
expenditure as a proportion of the national 
health budget’ – the SA government’s curr-
ent allocations to health research are far 
below the aspirational target of 2% allocation 
of the national health budget to health 
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Table 2. Estimate of expenditure on health research by the South African government during the period 2009 - 2013
Government budget
2009/10 2010/11 2011/12 2012/13
Total R832.5bn* R885.8bn* R964.4bn* R1 042.9bn*
Consolidated government expenditure on health R91.4bn* R100.2bn* R114.1bn* R126.0bn*
Health Vote R45.2bn* R27.2bn* R55.3bn* R33.1bn† 
Health research expenditure through the Health Vote R417.9m R368.7m R403.0m R448.3m 
Health research expenditure through the Health Vote,  
as % of total government health expenditure
0.46% 0.37% 0.35% 0.36%
Health research expenditure through the Health Vote,  
as % of total Health Vote
0.92% 1.36% 0.73% 1.35%
Research recipients
HST R2.8m* R4.9m* R6.1m* R8.3m†
HIMME R39.1m* R21.6m* R51.9m* R43.2m†
HRPRP R17.2m* R8.5m† R9.6m† Not known
NHLS R136.1m* R96.4m* R97.5m* R100m†
MRC R222.7m* R237.3m* R237.9m* R296.8m†
Total R417.9m R368.7m R403.0m R448.3m
bn = billion; m = million; HST = Health Systems Trust; HIMME = Health Information Management, Monitoring and Evaluation; HRPRP = Human Resources Policy Research and Planning;  
NHLS = National Health Laboratory Service; MRC = Medical Research Council.
*Actual expenditure outcome.
†Forecast budget.
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research. These data suggest that health 
research expenditure by the government 
would need to at least double in order to 
provide appropriate levels of investment in 
health research and to approach the levels 
to which it has previously committed itself.
The data presented here demonstrate, 
however, that in contrast to general per-
ception, total SA investment in health 
research from the aggregated public, private 
and foreign sectors has increased steadily 
in real terms during recent years judged 
by several metrics, a trend that seems set 
to continue in the short term at least. For 
example, the percentage of the GDP spent 
on R&D was 0.87% in 2009/10, GERD 
increased 2-fold in real terms from 1994 to 
2009/2010, the percentage of GERD spent 
on health research was 16.7% in 2009/10, 
the government sector expenditure on 
R&D increased 4-fold in real terms from 
1991/2 to 2009/10, and the total health 
research expenditure increased 2.6-fold in 
real terms from 1994 to 2009/10. However, 
we note that this total investment in health 
research in 2009/10 equated to only 0.15% 
of the GDP (GERD being 0.87% of the GDP 
and 16.7% of GERD being spent on health 
research), meaning that total investment 
in health research would need to at least 
double in order to approach the ASSAf 
target of 0.4% of the GDP and thereby 
provide appropriate levels of investment in 
health research in SA.
The global disparity in the distribution 
of funds for health R&D has resulted in 
many developing countries spending lower 
proportions of their GDP on health research, 
despite a high proportion of disease burden. It 
is therefore not surprising that in developing 
countries there is a perceived lack of capacity 
to develop innovative technologies to meet 
the health needs of the population. There is a 
concerted effort driven by the World Health 
Organization to redress these inequities. 
The Consultative Expert Working Group 
on Research and Development: Finance 
and Co-ordination (CEWG) has proposed 
novel strategies to incentivise, co-ordinate 
and sustain heath research in developing 
countries.[25] The CEWG proposes that all 
countries commit to contributing at least 
0.01% (0.15 - 0.2% for developed countries) 
of the GDP on government-funded health 
R&D. They additionally recommend that 
the funds be pooled and managed centrally 
so that developing countries receive 20 - 
50% of the pooled funds. We suggest that 
these CEWG recommendations provide a 
more tangible and transparent aspiration 
and means to enable properly funded health 
research in SA than the current confused 
‘2% of national health budgets to research’ 
commitments. We therefore recommend 
that the CEWG proposals should be adopted 
by the SA government without delay.
The data presented here show that in 
2009/10 the proportion of the R3.5 billion 
total health expenditure in 2009/10 attri-
butable to SA government funding was only 
R729 million, meaning that government-
funded health R&D constituted only 0.03% 
of the GDP in that year, close to the bottom of 
the CEWG-recommended range. Once again, 
these data suggest that there is considerable 
scope to increase government sector invest-
ment in health research immediately.
Among others, the data presented here 
illustrate the need to develop an efficient 
monitoring mechanism to track the level of 
expenditure on health research by govern-
mental and non-governmental funders 
in the national health research system so 
that performance against international 
benchmarks can be assessed accurately. Such 
a national information system for health 
research expenditure will also be invaluable 
in enabling accurate assessment of whether 
health research funding is being effectively 
utilised to address SA healthcare priorities, 
and in addition will provide a means to 
better co-ordinate the activities of different 
Singapore
Iceland
Switzerland
Denmark
UK
2 4 10 14
Sweden
Belgium
Japan
Canada
USA
Netherlands
Finland
Turkey
Austria
France
Israel
Norway
Australia
Germany
6 8 12
Health R&D, % of national health budget
Ireland
Italy
South Africa
Spain
Poland
Portugal
Romania
India
China
Brazil
Greece
Russia
Tobago
Uruguay
Guatemala
Ecuador
Fig. 6. Health research and development expenditure as a proportion of the national health expenditure 
in 2005. (R&D = research and development.)
FORUM
474       July 2014, Vol. 104, No. 7
government departments in the health research arena. As such, it 
should form a cornerstone of plans for the new National Health 
Research Observatory in SA now being developed by the NHRC.
A new consensus is emerging on the fundamental importance 
of a national health research system as an integral component in 
strength ening the public sector delivery system in preparation 
for the new National Health Insurance (NHI) system, the aim of 
which is to achieve a long and healthy life for all SA citizens.[26] The 
procurement and allocation of funds for research is one of the central 
functions of a health research system,[2] and the need for increased 
investment in R&D has been recognised. It is therefore of concern 
that, using the annual baseline allocations to the MRC in the period 
2007/8 - 2011/12 as a barometer, the proportion of the budget of the 
national DoH that has been allocated to health research has been in 
decline in real terms in recent years, despite the fact that SA faces 
an unprecedented burden of infectious and non-communicable 
diseases. One step in the right direction will therefore be for the 
national DoH to progressively increase the percentage of the Health 
Vote allocated to health research, and we note encouraging signs of 
this in the 2013 Estimates of National Expenditure,[17] which forecast 
an increase in the MRC’s baseline funding to R616 million in 2015/16, 
constituting a 26.8% average growth rate in nominal terms in the 
period 2011/12 - 2015/16. In addition, we note the recent launch of the 
new National Health Scholars Programme and the Strategic Health 
Innovation Partnership – both of which are partially supported by 
new budgets from the national DoH – as further evidence of progress 
towards developing new funding streams for expenditures on health 
research under the national DoH and its entities.
In conclusion, it seems clear from our analysis that neither the 
aspirational public commitments made by the the SA Ministry 
of Health to specific levels of funding of health research, nor the 
goals for funding of health research set out in the National Health 
Research Policy (2011), have been met and indeed that they may not 
be achievable in full in the short term. We therefore recommend that 
a new set of realistic, transparent, internationally accepted and more 
clearly defined targets be adopted forthwith as a means to ensure 
adequate future government investment in health research in SA.
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